Acute hyperglycaemia causes elevation in plasma atrial natriuretic peptide concentrations in Type 1 diabetes mellitus

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

To examine the effect of acute hyperglycaemia on atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) concentrations in Type 1 diabetes.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

Eight Type 1 diabetes subjects were clamped at euglycaemia by intravenous infusion of insulin.

One week later, each subject received the alternate infusion.

How the Study Was Run

In design terms this was a randomized and single-blind study.

The participants were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether ANP (Atrial Natriuretic Peptide) was given.

The study was two limb, randomized, and single-blind.

Blood was collected for estimation of plasma glucose, ANP and BNP concentrations at 30 min intervals for 2 h from the start of the infusion period.

Results are expressed as mean +/- standard deviation, and were analysed by ANOVA.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Blood Glucose, Diabetes Mellitus, Type 1, Glucose Clamp Technique, Hyperglycemia, Insulin and Natriuretic Peptide, Brain.

What This Means in Plain Language

The paper is a randomized and single-blind study of ANP (Atrial Natriuretic Peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.